Galderma Group AGXSWX:GALD -0.14%15 Days Payable is 165.28 as of Dec. 2025, which is 3% above its 10-year median of 160.90. GuruFocus rates XSWX:GALD with a GF Score™ of 15/100. The stock has 4 warning signs investors should review. Among 923 Drug Manufacturers companies, Galderma Group AG ranks better than 78.33% on this metric.
The historical rank and industry rank for Galderma Group AG's Days Payable or its related term are showing as below:
XSWX:GALD'
s Days Payable Range Over the Past 10 Years
Min: 149.67 Med: 160.9 Max: 165.02
Current: 163.68
During the past 5 years, Galderma Group AG's highest Days Payable was 165.02. The lowest was 149.67. And the median was 160.90.
XSWX:GALD's Days Payable is ranked better than 78.33% of 923
companies
in the Drug Manufacturers industry
Industry Median: 90.98
vs XSWX:GALD: 163.68
Galderma Group AG's Days Payable
increased
from Dec. 2024 (162.95) to Dec. 2025 (165.28).
It may suggest that Galderma Group AGdelayed paying its suppliers.
Galderma Group AG Days Payable Related Terms
Galderma Group AG Days Payable Historical Data
* Premium members only.
The historical data trend for Galderma Group AG's Days Payable can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
XSWX:GALD vs ZTS, UTHR, VTRS: Days Payable Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Galderma Group AG's Days Payable, along with its competitors' market caps and Days Payable data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Galderma Group AG Days Payable vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Galderma Group AG's Days Payable distribution charts can be found below:
* The bar in red indicates where Galderma Group AG's Days Payable falls into.
Days Payable indicates the number of days that the account payable relative to cost of goods sold the company has. An increase of Days Payable may suggest that the company delays paying its suppliers.
Galderma Group AG's Days Payable for the fiscal year that ended in Dec. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Galderma Group AG (XSWX:GALD) has a Days Payable of 165.28 as of Dec. 2025. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on Galderma Group AG and its competitors. This is near median its historical median of 160.90. Over the past decade, Galderma Group AG's Days Payable has ranged from 149.67 to 165.02. According to the industry distribution chart, Galderma Group AG ranks #200 out of 923 companies in the Drug Manufacturers industry, placing it in the top 21.7%.
Is Galderma Group AG's Days Payable too high?
Galderma Group AG's current Days Payable of 165.28 is near median its 10-year median of 160.90. Over the past 10 years, this metric has ranged from a low of 149.67 to a high of 165.02. The Drug Manufacturers industry median Days Payable is 90.98. Galderma Group AG's value of 165.28 is 81.7% above this industry median. Based on the distribution chart, Galderma Group AG ranks #200 out of 923 companies in the Drug Manufacturers industry, which is in the top quartile — a strong position relative to peers. Overall, Galderma Group AG has a GF Score™ of 15/100, reflecting its overall financial health beyond just this single metric.
How does Galderma Group AG's Days Payable compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Galderma Group AG ranks #200 out of 923 companies for Days Payable. This places Galderma Group AG in the top 22% of its industry — outperforming the majority of peers. The industry median Days Payable is 90.98. Galderma Group AG's value of 165.28 is 81.7% above this benchmark. Historically, Galderma Group AG's own Days Payable has ranged from 149.67 to 165.02 over the past decade. While the company's 10-year median is 160.90 vs. the industry median of 90.98, Galderma Group AG has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Days Payable for a Drug Manufacturers company?
The median Days Payable among Drug Manufacturers companies is 90.98, based on 923 companies in the industry. Companies in the top quartile (top 25%) have a Days Payable significantly above this median, while those in the bottom quartile fall well below. However, Days Payable should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Galderma Group AG's current Days Payable of 165.28 is 81.7% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Days Payable mean?
A high Days Payable can signal that a stock is expensive relative to its fundamentals. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on Galderma Group AG and its competitors. For the Drug Manufacturers industry, the median Days Payable is 90.98 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Galderma Group AG's current Days Payable is 165.28, which is near median its own 10-year median of 160.90. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Galderma Group AG stock overvalued right now?
Galderma Group AG (XSWX:GALD) has a current Days Payable of 165.28. The current Days Payable is 165.28, which is near median its 10-year median of 160.90 and 81.7% above the Drug Manufacturers industry median of 90.98. Galderma Group AG's overall GF Score™ is 15/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Days Payable calculated?
Days Payable is calculated from a company's financial statements. For Galderma Group AG (XSWX:GALD), the current Days Payable is 165.28 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Galderma was formed in 1981 as a joint venture between Nestle and L'Oreal. It subsequently became a subsidiary of Nestle, called Nestle Skin Health, before being carved out and launched as a stand-alone company in 2019, acquired by a consortium led by Sweden-based EQT fund. The company went public in March 2024 and is listed on the SIX Swiss exchange. Galderma's science-based portfolio spans multiple dermatology categories, including injectable aesthetics, dermatological skincare, and therapeutic dermatology. It derives around 40% of net sales from the US and employs more than 7,500 people.
15GF Score
Get the complete analysis for XSWX:GALD
Days Payable is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
XSWX:GALD has been successfully added to your 